
News|Slideshows|May 14, 2026
2026 AAN Annual Meeting: Top Interviews and Expert Perspectives
Author(s)Louie Pasculli
Fact checked by: Marco Meglio
Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.
Advertisement
Advertisement
The 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22, in Chicago, Illinois, brought together thousands of clinicians, researchers, trainees, and industry leaders for one of the field’s premier neurology conferences. This year’s meeting featured plenary sessions focused on ongoing controversies in neurology, presentations highlighting advances in translational science, late-breaking clinical data, award lectures, and discussions spanning nearly every subspecialty in neurology.
Related to this article

The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.

FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.

New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
Advertisement
Advertisement


